SCHEMBL87385

SCHEMBL87385

CCCSc1ccc2ncn([C@@H](CC)C(=O)OC(C)(C)C)c(=O)c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
MAPK1 P28482 2/20 0.37
GAA P10253 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
KCNH2 Q12809 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 1/20 0.34
USP5 P45974 1/20 0.33
TNF P01375 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78193 0.87 USP5 (0.43) LMNAMAPK1GAAALDH1A1HPGD
SCHEMBL78192 0.87 USP5 (0.43) LMNAMAPK1GAAALDH1A1HPGD
SCHEMBL92945 0.85 LMNA (0.37) LMNAMAPK1GAAALDH1A1HPGD
SCHEMBL78194 0.83 GAA (0.48) LMNAMAPK1GAAALDH1A1HPGD
SCHEMBL80598 0.74 CASP1 (0.39)
SCHEMBL10072149 0.74 CASP1 (0.39)
SCHEMBL13632275 0.73 CASP1 (0.34)
SCHEMBL6385632 0.72 USP5 (0.48) LMNAMAPK1ALDH1A1KMT2ATP53
SCHEMBL79412 0.72 USP5 (0.48) LMNAMAPK1ALDH1A1KMT2ATP53
SCHEMBL78933 0.68 USP5 (0.41) ALDH1A1TSHRUSP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129381-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-12 US disclosed
US-7553852-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-30 US disclosed
US-7553852-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-30 US disclosed
WO-2004002961-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF CASP1, CASP5, CASP3 LMNA 147/4885MAPK1 942/4885GAA 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.